Sign up to save your podcasts
Or
Share Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
CME credits: 1.00
Valid until: 02-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/advancing-molecular-therapies-to-first-line-in-braf-mutated-mcrc-insights-from-emerging-data/36506/
This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 1.00
Valid until: 02-12-2026
Claim your CME credit at https://reachmd.com/programs/cme/advancing-molecular-therapies-to-first-line-in-braf-mutated-mcrc-insights-from-emerging-data/36506/
This series provides expert perspectives on the management of metastatic colorectal cancer (mCRC), with a focus on the timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, and the management of treatment-related adverse events.